RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNISING GANGLIOSIDE N-GLYCOLYL-GM3 AND USE THEREOF IN THE DIAGNOSIS AND TREATMENT OF TUMOURS

The invention essentially relates to the production of less immunogenic immunoglobulins by means of genetic engineering and, more specifically, to a monoclonal antibody recognizing antigens which contain the N-glycolil GM3 ganglioside but not other gangliosides of the N-glycolil or N-acetyl type, or...

Full description

Saved in:
Bibliographic Details
Main Authors MATEO DE ACOSTA DEL RIO CRISTINA MARIA, MORENO FRIAS ERNESTO 5TA AVENIDA EDIFICIO BBE, ROQUE NAVARRO LOUDES TATIANA, RODRIGUEZ GONZALEZ MABEL CONSEJAL VEIGA NO 110, ROJAS DORANTES GERTRUDIS, TALAVERA PEREZ ARIEL
Format Patent
LanguageEnglish
Slovenian
Published 31.07.2015
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention essentially relates to the production of less immunogenic immunoglobulins by means of genetic engineering and, more specifically, to a monoclonal antibody recognizing antigens which contain the N-glycolil GM3 ganglioside but not other gangliosides of the N-glycolil or N-acetyl type, or the sulphated glycolipids. In particular the invention relates to peptides sequences encoding a recombinant monoclonal antibody against the N-glycolil GM3 ganglioside, or derivative fragments of the same. The invention further relates to pharmaceutical compositions containing the aforementioned antibody or fragments thereof and to the diagnostic or therapeutic use of same for breast cancer and melanoma.
Bibliography:Application Number: SI20040032242T